JP2024510503A - 血漿カリクレイン阻害剤 - Google Patents

血漿カリクレイン阻害剤 Download PDF

Info

Publication number
JP2024510503A
JP2024510503A JP2023557352A JP2023557352A JP2024510503A JP 2024510503 A JP2024510503 A JP 2024510503A JP 2023557352 A JP2023557352 A JP 2023557352A JP 2023557352 A JP2023557352 A JP 2023557352A JP 2024510503 A JP2024510503 A JP 2024510503A
Authority
JP
Japan
Prior art keywords
pyridin
mmol
methyl
nitrogen
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557352A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510503A5 (https=
JPWO2022197756A5 (https=
Inventor
パパイオアンヌー，ニコラス
マーク トラヴィンス，ジェレミー
ジョセリン フィンク，サラ
マーク エラード，ジョン
レイ，アラステア
アンドリュー スペンサー，ジョナサン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2024510503A publication Critical patent/JP2024510503A/ja
Publication of JP2024510503A5 publication Critical patent/JP2024510503A5/ja
Publication of JPWO2022197756A5 publication Critical patent/JPWO2022197756A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023557352A 2021-03-17 2022-03-16 血漿カリクレイン阻害剤 Pending JP2024510503A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162477P 2021-03-17 2021-03-17
US63/162,477 2021-03-17
PCT/US2022/020479 WO2022197756A1 (en) 2021-03-17 2022-03-16 Plasma kallikrein inhibitors

Publications (3)

Publication Number Publication Date
JP2024510503A true JP2024510503A (ja) 2024-03-07
JP2024510503A5 JP2024510503A5 (https=) 2025-03-24
JPWO2022197756A5 JPWO2022197756A5 (https=) 2025-03-24

Family

ID=81327137

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557352A Pending JP2024510503A (ja) 2021-03-17 2022-03-16 血漿カリクレイン阻害剤

Country Status (5)

Country Link
US (1) US20240382482A1 (https=)
EP (1) EP4308228A1 (https=)
JP (1) JP2024510503A (https=)
CN (1) CN117396474A (https=)
WO (1) WO2022197756A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200143376A (ko) 2018-03-13 2020-12-23 샤이어 휴먼 지네틱 테라피즈 인크. 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도
CN114667289B (zh) 2019-09-18 2025-08-26 武田药品工业有限公司 杂芳基血浆激肽释放酶抑制剂
EP4031547B1 (en) 2019-09-18 2024-07-17 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof
CN117396473A (zh) * 2021-03-17 2024-01-12 武田药品工业株式会社 血浆激肽释放酶的咪唑并吡啶基抑制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500539A (ja) * 2007-10-12 2011-01-06 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤
WO2016010108A1 (ja) * 2014-07-18 2016-01-21 塩野義製薬株式会社 含窒素複素環誘導体およびそれらを含有する医薬組成物
JP2017516826A (ja) * 2014-06-04 2017-06-22 トーマス・ヘレデイズ・スティフテルス・フォー・メディシンスク・フォルスクニング 炎症性および自己免疫性の病気の処置のためのｍｔｈ１阻害剤
WO2019178129A1 (en) * 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6887870B1 (en) * 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
EP2627178B1 (en) * 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
EP3087067B1 (en) * 2013-12-26 2018-10-24 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors
WO2016201052A1 (en) 2015-06-12 2016-12-15 Global Blood Therapeutics, Inc. Bridged bicyclic kallikrein inhibitors
IL263235B (en) 2016-05-31 2022-07-01 Kalvista Pharmaceuticals Ltd History of pyrazoles as plasma kallikrein inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500539A (ja) * 2007-10-12 2011-01-06 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤
JP2017516826A (ja) * 2014-06-04 2017-06-22 トーマス・ヘレデイズ・スティフテルス・フォー・メディシンスク・フォルスクニング 炎症性および自己免疫性の病気の処置のためのｍｔｈ１阻害剤
WO2016010108A1 (ja) * 2014-07-18 2016-01-21 塩野義製薬株式会社 含窒素複素環誘導体およびそれらを含有する医薬組成物
WO2019178129A1 (en) * 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"CAS登録番号 1386640-66-9", REGISTRY（STN）[ONLINE], JPN7025004934, 2012, ISSN: 0005733251 *
ROATSCH, MARTIN 他: "Substituted 2-(2-aminopyrimidin-4-yl)pyridine-4-carboxylates as potent inhibitors of JumonjiC domain", FUTURE MEDICINAL CHEMISTRY, vol. 8(13), JPN6025046682, 2016, pages 1553 - 1571, ISSN: 0005733250 *

Also Published As

Publication number Publication date
WO2022197756A1 (en) 2022-09-22
CN117396474A (zh) 2024-01-12
US20240382482A1 (en) 2024-11-21
EP4308228A1 (en) 2024-01-24

Similar Documents

Publication Publication Date Title
US11746120B2 (en) Stat degraders and uses thereof
JP7498200B2 (ja) Ｔｙｋ２阻害剤およびその使用
TWI834641B (zh) 血漿激肽釋放素抑制劑及其用途
EP3612030B1 (en) Indole ahr inhibitors and uses thereof
AU2018222943B2 (en) Heterocyclic compounds useful as PDK1 inhibitors
RU2505538C2 (ru) Новые пиридиноны и пиридазиноны
EP3122353B1 (en) Substituted indole mcl-1 inhibitors
US8530489B2 (en) 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors
JP5243970B2 (ja) タンパク質キナーゼの阻害剤として有用なジヒドロジアゼピン
JP2024510503A (ja) 血漿カリクレイン阻害剤
JP2023546996A (ja) Ｃｔｐｓ１阻害剤およびその使用
EP3071205A1 (en) Benzopiperazine compositions as bet bromodomain inhibitors
TW201900612A (zh) 吲哚甲醯胺化合物
TW200820972A (en) 4-methylpyridopyrimidinone compounds
CN104136399B (zh) 泛素活化酶的吡唑并嘧啶基抑制剂
IL301501B1 (en) Antiproliferation compounds and uses thereof
WO2022197789A1 (en) Polycyclic inhibitors of plasma kallikrein
CN117396469A (zh) 血浆激肽释放酶的抑制剂
EA041983B1 (ru) Индольные ингибиторы арил-гидрокарбонового рецептора (ahr) и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250313

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260421